DAYTON, Ohio, Nov. 22 /PRNewswire/ -- Riverain Medical has introduced the
first and only artificial intelligence system with FDA PMA approval for CHEST
X-RAY early-stage Lung Cancer detection. In clinical trials, radiologists
working with RapidScreen's(R) computer aided detection technology demonstrated
a 23% increase in detection efficiency for lung nodules ranging from 9 to 14mm
in size. Detecting and treating more lung cancers in the earliest stage has
the potential to save 54,000 lives annually. The RapidScreen(R) early Lung
Cancer detection system is commercially available and will be at the RSNA -
Radiological Society of North America 90th Scientific Assembly and Annual
Meeting in Chicago from November 28 through December 3, 2004.
According to The American Cancer Society, Lung Cancer is the number one
cancer killer in the United States. In the U.S. alone, an estimated 160,000
lives are lost each year to lung cancer -- more than colon, breast, and
prostate cancer combined. Currently, only 15% of cancers are detected when
they are small solitary pulmonary nodules in the 9-14 mm size. Small lung
cancers found within this range present the most significant opportunity for
earlier treatment for patients. It is estimated that Lung Cancer caught at
this stage may be cured or controlled in up to 85% of all cases.
In clinical trials, radiologists working with RapidScreen(R) demonstrated
a 23% increase in detection efficiency for lung nodules ranging from 9-14 mm
in size. With over 71 million CHEST X-RAY exams given in the U.S. each year,
early-stage Lung Cancer screening with RapidScreen(R) represents a tremendous
opportunity to improve early detection and save additional lives. This tool
can help radiologists detect more small, subtle, and suspicious nodules at an
early stage.
"After initial screening and detection with RapidScreen(R) using routine
CHEST X-RAYS, complementary technologies such as CT may be used to further
characterize and confirm nodule identity," states Matthew Freedman, MD, of
Georgetown University Medical Center. Dr. Freedman, Professor of Oncology, is
a pioneer in applying Computer Aided Detection (CAD) technology to early-stage
Lung Cancer and a noted spokesman in the field. He adds, "CHEST X-RAY CAD
enhances the value of the CHEST radiograph. Clinical trials have demonstrated
that CAD prompt marks can increase the ability of radiologists to find
suspicious nodules in routine X-RAYS."
About Riverain Medical
Riverain Medical is a privately held corporation, located in Dayton, OH,
that provides CHEST X-RAY CAD and medical artificial intelligence computer
aided solutions to assist physicians in the detection of disease.
For more information on Riverain Medical and the RapidScreen(R) RS-2000
and RS-2000D products, please contact:
Greg Flittner, V.P. Marketing
937.425.6811 or 800.990.3387
gflittner@riveraingroup.com
SOURCE Riverain Medical
 back to top
Related links:
http://www.riverainmedical.com
CONTACT:
Greg Flittner, V.P. Marketing of Riverain
Medical, +1-937-425-6811, or +1-800-990-3387, or
gflittner@riveraingroup.com
|
